PILA PHARMA AB announced the postponement of its 2025 annual report and annual general meeting. The delay is not due to financial issues or audit complications but aims to provide updated information following preclinical obesity studies. The meeting will now be held in May, consistent with past practices. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and other inflammatory diseases. The company owns the TRPV1 asset XEN-D0501, which has shown promising results in clinical trials. PILA PHARMA plans to submit a clinical trial application for a dose-finding study in obesity by Q1 2026. The company also has plans for erythromelalgia, a rare disease, and is preparing a clinical trial application for it.

PILA PHARMA AB has announced a delay in the publication of its 2025 annual report, which is now expected to be available by April 21, 2026. This postponement has led to rescheduling the Company's Annual General Meeting to May 19, 2026, from the initially planned date of April 22, 2026. PILA PHARMA, a Swedish biotech company, is focused on developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promise in clinical trials for these conditions. The company is preparing to submit a clinical trial application by the end of Q1 2026 for further studies. PILA PHARMA also holds orphan drug designation for XEN-D0501 as a treatment for erythromelalgia, a rare disease with no current treatments. The company is exploring licensing opportunities for this candidate.

PILA PHARMA AB, a Swedish biotech company, announced its participation in the BIO-Europe Spring conference in Lisbon, Portugal, from March 23-25. The company's CEO, Gustav H. Gram, will represent PILA PHARMA to discuss its oral TRPV1 inhibitor drug candidate intended for obesity and related diseases, as well as erythromelalgia, for which it holds FDA orphan designation. The company aims to meet potential partners and update existing dialogues with pharmaceutical companies regarding its lead candidate. PILA PHARMA is preparing clinical trial applications for both obesity and erythromelalgia, with submissions expected by the end of Q1 2026. The company focuses on developing TRPV1 inhibitors for obesity, type 2 diabetes, and other inflammatory diseases, with its candidate XEN-D0501 showing promise in previous clinical trials. The company also holds patents related to the use of TRPV1 antagonists for treating obesity and diabetes.

PILA PHARMA AB, a Swedish biotech company, announced the conversion of TO2 warrants into shares, with company management participating in the process. The subscription period for the TO2 warrants was from February 5 to February 15, 2026, with a subscription price of SEK 1.50 per share. A total of 1,798,853 warrants were exercised, resulting in 3,597,706 new shares and a dilution of approximately 7.88% for non-participating shareholders. The company raised approximately SEK 5.4 million before costs, increasing the total number of outstanding shares to 45,682,121. CEO Gustav H. Gram and CSO Dr. Dorte X. Gram participated in the warrant exercise. The proceeds will support the clinical trial progression of the company's lead drug candidate, XEN-D0501, a TRPV1 inhibitor for obesity and erythromelalgia. PILA PHARMA focuses on developing TRPV1 inhibitors for obesity, type 2 diabetes, and other inflammatory diseases, with ongoing preparations for a clinical trial application by Q1 2026. The company owns patents related to TRPV1 antagonists and seeks licensing opportunities for further development.

PILA PHARMA AB, a biotech company focused on developing oral drugs based on TRPV1 inhibition, announced the results of its TO2 warrant exercise. During the subscription period from February 5 to February 15, 2026, 1,798,853 warrants were exercised to subscribe for 3,597,706 shares at SEK 1.50 per share, raising approximately SEK 5.4 million before costs. This exercise resulted in a 7.88% dilution for non-participating shareholders. CFO Hampus Darrell stated that the funds strengthen the company's financial position, extending its cash runway into the first half of 2027. CEO Gustav H. Gram expressed gratitude to shareholders and noted the funds would support the company's clinical obesity trial. PILA PHARMA plans to provide updated financial and clinical guidance soon. The company, listed on Nasdaq First North Growth Market, focuses on developing TRPV1 inhibitors for obesity, type 2 diabetes, erythromelalgia, and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promise in clinical trials. PILA PHARMA aims to further develop this candidate and submit a clinical trial application for a dose-finding study by the end of Q1 2026.

PILA PHARMA AB announced the results of the exercise of warrants of series TO2, issued during the company's rights issue in the third quarter of 2025. A total of 1,798,853 warrants were exercised, representing approximately 12.03% of the outstanding warrants, leading to the subscription of 3,597,706 shares at SEK 1.50 per share. This exercise will generate about SEK 5.4 million for the company before costs. The subscription period was from February 5 to February 15, 2026. The total number of shares will increase to 45,682,121, with a share capital increase of SEK 153,824.01. Existing shareholders who did not exercise their warrants will experience a dilution of approximately 7.88%. MAQS Advokatbyrå and Nordic Issuing served as legal advisor and issuing agent, respectively. PILA PHARMA, based in Malmö, Sweden, focuses on developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and other inflammatory diseases. Their development candidate, XEN-D0501, has shown promise in clinical trials for obesity and diabetes and has orphan drug designation for erythromelalgia. The company is preparing to submit a clinical trial application for further studies by the end of Q1 2026. The press release includes legal disclaimers regarding distribution and investment risks and outlines the forward-looking statements about the company's future operations and market prospects.

PILA PHARMA AB has announced that February 15, 2026, is the final day for exercising warrants of series TO2, which allow holders to subscribe for two new shares in the company at a price of SEK 1.50 per share. If fully exercised, the company could raise approximately SEK 44.87 million before costs. Holders must actively subscribe for new shares to prevent the warrants from expiring without value. The exercise period runs from February 5 to February 15, 2026, but some platforms may close applications earlier. The full terms and a prospectus approved by the Swedish Financial Supervisory Authority are available on the company's website. The exercise outcome will be announced around February 16, 2026. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and other inflammatory-related diseases. Their candidate, XEN-D0501, has shown promise in clinical trials and is moving towards further studies. The company also explores licensing opportunities for erythromelalgia and other conditions. The press release includes legal disclaimers and information for distributors regarding the investment's risks and target market.

PILA PHARMA AB, a Swedish biotech company focused on developing novel oral drugs based on TRPV1 inhibition, hosted a live online interview and Q&A session with CEO Gustav H. Gram on February 10, 2026, in collaboration with Infront Direkt Studios. The session, which can be replayed online, was held in conjunction with the release of the company's H2/Year-end report. During the interview, Gram discussed the company's financial status, recent preclinical studies, the ongoing TO2 warrant period, future clinical plans for obesity treatment, and clinical preparations for erythromelalgia. PILA PHARMA, listed on Nasdaq First North Growth Market, is advancing the development of XEN-D0501, a TRPV1 inhibitor, for treating obesity, type 2 diabetes, and potentially other inflammatory diseases. The company has completed two phase 2a clinical trials demonstrating the drug's tolerability and effectiveness in enhancing insulin response. A clinical trial application for a dose-finding study in obesity is planned for submission by the end of Q1 2026. Additionally, PILA PHARMA is exploring licensing opportunities for erythromelalgia and abdominal aorta aneurysm treatments. The company aims to address the global obesity and diabetes pandemics, which have significant health impacts and economic costs. Erythromelalgia, a rare disease with no current treatments, is also a focus for future development.

PILA PHARMA AB, a Swedish biotech company focused on developing TRPV1 inhibitors for obesity, type 2 diabetes, and other inflammatory diseases, will host a live online interview and Q&A session on February 10, 2026. The event, featuring CEO Gustav H. Gram, coincides with the release of the company's H2/Year-end report. Key topics include the company's cash position, recent preclinical studies, the TO2 warrant period, future clinical plans for obesity, and clinical preparations for erythromelalgia. Attendees can submit questions via email or chat, and the session will be available for later viewing. PILA PHARMA, listed on Nasdaq First North Growth Market, is advancing its drug candidate XEN-D0501, which has shown promise in clinical trials for obesity and type 2 diabetes. The company is preparing a clinical trial application for a dose-finding study in obesity by Q1 2026. Additionally, PILA PHARMA holds patents for TRPV1-antagonists and seeks licensing opportunities for erythromelalgia and other conditions. Obesity and diabetes are major global health concerns, with significant unmet needs for effective treatments. Erythromelalgia, a rare disease causing severe pain and inflammation, lacks current treatments, and PILA PHARMA is developing a clinical plan for this condition.

PILA PHARMA AB, a biotech company, is preparing a clinical trial application for a proof-of-concept study to develop its oral TRPV1 inhibitor as a treatment for erythromelalgia, a rare disease characterized by neurogenic inflammation and severe pain. The company received orphan drug designation from the FDA in 2022 and plans to conduct a smaller study to demonstrate the drug's efficacy before proceeding to phase 2/3 trials. The expected time to market is approximately three years, with potential regulatory exclusivity of seven years in the US post-approval. Erythromelalgia can cause debilitating pain, affecting quality of life and potentially increasing mortality and suicide rates. PILA PHARMA's founder expressed optimism about the drug's potential to alleviate pain and improve patients' lives. The company's scientific expert highlighted the benefits of the drug's tablet form, which could also prevent pain attacks. PILA PHARMA, based in Malmö, Sweden, focuses on developing TRPV1 inhibitors for obesity, type 2 diabetes, and other inflammatory diseases. The company has completed two phase 2a trials showing XEN-D0501's tolerability in obesity and diabetes patients. They plan to submit a clinical trial application for a dose-finding study in obesity by Q1 2026. Erythromelalgia currently lacks approved treatments, and PILA PHARMA aims to provide a systemic oral solution.

PILA PHARMA AB, a Swedish biotech company, announced it will release its interim report for the second half of 2025 on February 10, 2026, earlier than the initially planned date of February 26, 2026. The change is due to the report's early completion and to facilitate the Board of Directors' and CEO's warrant exercises. PILA PHARMA, based in Malmö, focuses on developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promise in clinical trials, demonstrating good tolerability and efficacy in enhancing insulin response in diabetic patients. The company plans to submit a clinical trial application for a dose-finding study in obese patients by the end of Q1 2026. Additionally, PILA PHARMA is exploring licensing opportunities for XEN-D0501 in treating erythromelalgia, a rare inflammatory disease. The company aims to address the growing demand for effective oral treatments for obesity and diabetes, which are global health concerns.

PILA PHARMA AB, a biotech company focused on developing a TRPV1 inhibitor, completed a rights issue of units, including shares and warrants, in the third quarter of 2025. Each warrant allows the holder to subscribe for two new shares at a price set at SEK 1.50, determined as 70% of the average market price, with an exercise period from February 5 to February 15, 2026. If all warrants are exercised, PILA PHARMA could raise approximately SEK 44.87 million before costs. The company's main project, XEN-D0501, targets obesity and type 2 diabetes, with plans to submit a clinical trial application by the end of Q1 2026. The company also explores licensing opportunities for treating erythromelalgia. PILA PHARMA's shares are traded on Nasdaq First North Growth Market, Sweden.